| |
| |
|
| Insider
Information: |
Drake Lorin |
| Relationship: |
|
| City: |
Schaumburg |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
39,172 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
39,172 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sagent Pharmaceuticals Inc |
SGNT |
|
2016-02-25 |
39,172 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
19 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2016-02-25 |
4 |
D |
$14.58 |
$4,884 |
D/D |
(335) |
39,172 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2016-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,214 |
39,507 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2016-02-22 |
4 |
D |
$13.00 |
$4,355 |
D/D |
(335) |
31,293 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2016-02-21 |
4 |
D |
$14.61 |
$6,560 |
D/D |
(449) |
31,628 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2016-02-18 |
4 |
D |
$15.16 |
$6,852 |
D/D |
(452) |
32,077 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2015-12-31 |
4 |
D |
$15.85 |
$13,520 |
D/D |
(853) |
32,529 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2015-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,480 |
33,382 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2015-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,683 |
27,902 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2015-02-22 |
4 |
D |
$28.50 |
$8,351 |
D/D |
(293) |
24,219 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2015-02-21 |
4 |
D |
$28.50 |
$12,797 |
D/D |
(449) |
24,512 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Executive VP, Sales |
• – – |
2015-02-18 |
4 |
D |
$27.22 |
$12,303 |
D/D |
(452) |
24,961 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Corporate VP, Sales |
• – – |
2014-02-22 |
4 |
D |
$21.75 |
$6,308 |
D/D |
(290) |
25,413 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Corporate VP, Sales |
• – – |
2014-02-21 |
4 |
D |
$21.84 |
$8,474 |
D/D |
(388) |
25,703 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Corporate VP, Sales |
• – – |
2014-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,960 |
26,091 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Corporate VP, Sales |
• – – |
2013-08-12 |
4 |
S |
$23.69 |
$23,690 |
D/D |
(1,000) |
21,478 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Corporate VP, Sales |
• – – |
2013-02-22 |
4 |
D |
$16.85 |
$5,847 |
D/D |
(347) |
21,131 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
Corporate VP, Sales |
• – – |
2013-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,924 |
22,478 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
VP, Sales and Marketing |
• – – |
2012-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,680 |
17,554 |
0 |
- |
|
| SGNT |
Sagent Pharmaceuticals In... |
VP, Sales and MarketingOfficer |
• – – |
2011-04-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,874 |
|
- |
|
19 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
